SRPT

Sarepta Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 0/10
  • Momentum↓ 2/10
Sarepta Therapeutics sales and earnings growth
SRPT Growth
Low
  • Revenue Y/Y↑ 47.15%
  • EPS Y/Y↓ -274.36%
  • FCF Y/Y↑ 19.06%
Sarepta Therapeutics gross and profit margin trends
SRPT Profitability
Neutral
  • Gross margin ↑ 76.30%
  • EPS margin↓ -11.20%
  • ROIC↓ -7.10%
Sarepta Therapeutics net debt vs free cash flow
SRPT Risk
Great
  • Debt / Equity↓ 0.9
  • Debt / FCF↓ 1.6
  • Interest coverage↓ NA

Sarepta Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗